Topic:

Venture Capital

Latest Headlines

Latest Headlines

Iconic Therapeutics snags $40M for eye disease R&D

South San Francisco's Iconic Therapeutics raised $40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with its ocular melanoma program.

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.

Accelerator's second NYC biotech startup sets out with $17M and some Gates-backed science

Accelerator, among the financiers looking to kick-start a fledgling biotech hub in New York City, launched its second local project in the form of Lodo Therapeutics, a company working to turn natural products into novel therapies.

OrbiMed backs China's Zai Lab in a $100M B round

Shanghai-headquartered drug developer Zai Lab said it locked up more than $100 million in Series B financing, raising cash from a syndicate including OrbiMed and Sequoia Capital.

Roche leads $175M investment in oncology software player Flatiron

Roche has led a $175 million investment in Flatiron Health, the oncology software player set up by a pair of former Google employees in 2012. The deal, which also sees Roche sign up to use Flatiron's services, continues the Big Pharma's drive to connect its R&D teams to a broader pool of data.

Pre-JP Morgan VC dealapalooza: Alector, NextCure and Cortexyme raise more than $100M

The start of every new year comes with a traditional blast of biopharma deal news in the week ahead of the annual JP Morgan confab. Here's a snapshot of the dealapalooza going on right now.

Bavarian Nordic eyes $86M Nasdaq IPO to advance cancer, infectious disease pipeline

Bavarian Nordic is turning to Nasdaq to bankroll the advance of its pipeline of infectious disease and cancer vaccines. The decision follows a breakout two-year period for the long-running company, in which alliances with Bristol-Myers Squibb and Johnson & Johnson raised investor expectations for its pipeline products.

Basilea seeks partner for PhIII antibiotic trial after canning Nasdaq IPO

Basilea Pharmaceutica has come out of talks with the FDA with a clearer idea of how it will design Phase III trials of its broad-spectrum antibiotic. But with its ambition to list on Nasdaq consigned to the scrapheap, Basilea is now steadfast in its desire to find a partner before kicking off the trials.

TiGenix ends 2015 on a high after filing for Nasdaq IPO

TiGenix is set to learn whether Wall Street will be more receptive to biotech IPOs this year than it was at the back end of 2015. The cell therapy specialist filed to list on Nasdaq just before Christmas, sparking a 20% rise in its stock price in Europe in the final days of the year.

Biogen backs Rodin's Alzheimer's efforts in a $500M deal

Rodin Therapeutics recruited Biogen to help advance its novel approach to Alzheimer's disease in a pairing that could end with the Atlas Venture company getting bought for $485 million.
'